Gilead Sciences Profile

0.35  0.51%
Last 1 Month(s)
Trading Day 

Exercise or conversion by Paul Carter of 2000 shares of Gilead Sciences subject to Rule 16b-3

Gilead Sciences Inc insider trading alert for exercise of common stock by Paul Carter, EVP Commercial Ops, on April 21, 2017. This event was filed by Gilead Sciences Inc with SEC on 2014-10-03. Statement of changes in beneficial ownership - SEC Form 4. Paul Carter is currently serves as executive vice president - commercial operations of Gilead Sciences [view details]   

Gilead Sciences Summary

Gilead Sciences made a $10 billion bet and lost.? They invested heavily into a drug that was denied release by the FDA.? Naturally, the stock was sold off sharply.? While the stock was sitting at highs of nearly $50.00, it is now a mere 10% of the level now.? But, just because the stock is beaten down as it is, does that mean it is a bad bet? ? [more]
Gilead Sciences Inc (GILD) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 8,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification and specializes in Healthcare with concentration in Pharmaceuticals And Biosciences. The company currently falls under 'Mid-Cap' category with current market capitalization of 6.69 B. Gilead Sciences Inc conducts business under Healthcare sector and is part of Pharmaceuticals And Biosciences industry. This company has 1.56 B outstanding shares of which 15.82 M shares are currently shorted by private and institutional investors with about 1.65 trading days to cover. GILEAD SCIENCES currently holds about 616.93 M in cash with 74.41 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.31.
Check Gilead Sciences Probability Of Bankruptcy

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Bank Of MontrealCommon Shares2.5 M171.6 M
Candriam Luxembourg ScaCommon Shares1.5 M103.1 M
View Gilead Sciences Diagnostics

Selected Gilead Sciences Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Gilead Sciences Against Markets

Gilead Sciences Leadership

John Martin Chairman and CEO, MBA
Kathleen Watson Executive Vice President - Human Resources
More Executives

Gilead Sciences Diversification Suggestion

Use Gilead Sciences to enhance returns of your portfolios. The stock experiences moderate upward volatility. Check odds of Gilead Sciences to be traded at 75.43 in 30 days
Risk Adjusted
Performance Score (0 to 100)
Chance of
< 1% 
Gilead Sciences Inc., a researchbased biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the AsiaPacific. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameGilead Sciences Inc
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock
RegionNorth America
Business Address333 Lakeside Drive, Foster City, CA 94404, United States
Foreign Associates
CIK Number00882095.0
MarketPharmaceuticals And Biosciences
Contact Number650 574 3000
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Bond Rating


Gilead Sciences Analyst Recommendations
Target PriceAdvice# of Analysts
Gilead Sciences Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Gilead Sciences Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Gilead Sciences Earnings Estimates
EPSEstimate Date
Quarterly Estimate2.15April 27, 2017
Gilead Sciences Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate